It remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for
Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and …

Introduction Ticagrelor is an oral, reversible, direct-acting P2Y 12 receptor inhibitor
approved for the prevention of cardiovascular events in acute coronary syndrome (ACS). In …

Purpose Ticagrelor is an orally administered, reversibly binding, direct-acting P2Y 12
receptor antagonist previously evaluated in several phase III trials. This phase IV …

BACKGROUND: Dual antiplatelet therapy with a potent P2Y12 inhibitor coupled with aspirin
for 1 year is the recommended treatment for patients with acute coronary syndrome (ACS) …

Background: The risk/benefit tradeoff of dual antiplatelet therapy after percutaneous
coronary intervention may vary in East Asian patients as compared with their non-East Asian …

Dual antiplatelet therapy (DAPT) with ticagrelor or adjusted‐dose prasugrel has been used
for acute coronary syndrome (ACS). However, few studies have directly compared these two …

Background: There was still conflict on the antithrombotic advantage of ticagrelor versus
clopidogrel among East Asian population with acute coronary syndrome (ACS). We …

Background Bleeding complications are associated with unfavorable outcomes in patients
with acute coronary syndrome (ACS). Compared to Whites, several studies demonstrated a …

Acute coronary syndrome (ACS) is a dangerous and urgent clinical pattern of coronary
artery disease. Aspirin and adenosine diphosphate P2Y12 receptor antagonists are the …

Purpose Previous trials have demonstrated that ticagrelor was superior to clopidogrel in
acute coronary syndrome (ACS) patients. However, several recent studies showed that …